STC-15 is under clinical development by Storm Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STC-15’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STC-15 overview

STC-15 is under development for the treatment of acute myeloid leukaemia (AML) and other solid cancers. The drug candidate acts by targeting methyltransferase-like protein 3 (METTL3). It is administered through an oral route.

Storm Therapeutics overview

Storm Therapeutics is a drug discovery company. It is focused on developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer and other diseases. The company is engaged in modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases. It utilizes latest insights and emerging data from its collaborations build a unique target discovery platform for the identification of new drug targets. The company partners with the research groups using cutting-edge techniques such as chemical biology, RNA-Seq and RNA mass spectrometry to identify their protein writers, readers and erasers. The company is a spin off from University of Cambridge. Storm Therapeutics is headquartered in Cambridge, England, the UK.

For a complete picture of STC-15’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.